Participated · Series B · Aug 2026

Mironid develops first-in-class small-molecule LoAc® drug candidates that directly target abnormally high kidney cAMP levels that drive cyst formation in ADPKD. Its lead programmes are focused on treating Autosomal Dominant Polycystic Kidney Disease, a hereditary disorder affecting over 12 million people worldwide with about 50% of patients developing kidney failure by age 60. The company was founded through collaboration between the University of Strathclyde and Heriot-Watt University and is led by CEO Neil Wilkie. Mironid has progressed a series of drug-development programmes targeting specific enzymes to generate differentiated therapies for diseases with high unmet need. The recently closed £34m Series B, which includes an £8.4m equity investment from SNIB and participation from Roche Venture Fund, Epidarex Capital, Sofinnova Partners, BioGeneration Ventures and the University of Strathclyde, will fund clinical development and advancement of its lead candidate.

Led · Series B · Jun 2026

COUR Pharma develops first-in-class antigen-specific immune tolerance therapies using a proprietary nanoparticle platform that encapsulates disease-relevant antigens to reprogram autoimmune responses. Its lead program, CNP-103, encapsulates four recombinant proteins and is designed to induce tolerance to antigens driving type 1 diabetes; it is currently in a Phase 2 randomized, double-blind, placebo-controlled trial (NCT06783309) in recently diagnosed adolescents and adults. COUR says the proteins in CNP-103 are believed to cover over 95% of known T1D-driving antigens and aims to prevent further islet cell destruction and preserve insulin production. The company is pursuing partnerships to advance CNP-104 for primary biliary cholangitis and CNP-106 for myasthenia gravis. COUR recently raised $50 million in a Series B to support the clinical advancement of CNP-103, with participation from strategic and venture investors including Lumira Ventures, Roche Venture Fund, and Sanofi.

Led · Equity · Nov 2025

Manifold Bio has built the mDesign AI-guided discovery platform, which directly measures thousands to millions of biologic variants inside living systems to generate highly predictive data for drug design. This direct-to-vivo approach enables the rapid creation of tissue-targeted medicines—including antibodies, siRNAs, ASOs, and other biologics—by systematically identifying shuttles that move therapeutic payloads across biological barriers such as the blood–brain barrier (BBB). The company is already applying its technology to discover next-generation BBB shuttles that leverage multiple receptor portals to transport drugs into the brain. Manifold describes its long-term vision as constructing the world’s first “virtual organism” model, powered by the large-scale in vivo data it collects. Financially, the firm just secured a $55 million upfront payment from Roche, with the possibility of earning more than $2 billion in milestones and tiered royalties, providing significant non-dilutive capital for future growth. Manifold may also co-fund one of the partnered programs in exchange for enhanced royalties and retains freedom to apply its BBB shuttle technology to other internal or partnered initiatives.

Led · Equity · Oct 2025

Mission Therapeutics is a clinical-stage biotechnology company headquartered in Cambridge, UK, focused on promoting the removal of dysfunctional mitochondria to restore cellular health. Its lead candidate, MTX325, inhibits the mitochondrial DUB enzyme USP30 and is being advanced for central-nervous-system disorders, with an upcoming Phase Ib proof-of-mechanism study in Parkinson’s disease patients. A second program, MTX652, targets peripheral indications using the same mitophagy-enhancing approach. Recent Phase Ia studies, including PET imaging, confirmed that MTX325 penetrates functional brain tissue in healthy volunteers, de-risking further clinical work. The company’s development efforts are additionally supported by a $5.2 million grant from the Michael J. Fox Foundation and Parkinson’s UK. Mission Therapeutics is led by Executive Director Dr. Anker Lundemose, Chief Development Officer Dr. Sarah J. Fritchley, and Chairman Dr. James B. Summers.

Participated · Series B · Jun 2025

SpliceBio is a clinical-stage genetic medicines company pioneering a Protein Splicing platform that uses engineered inteins to enable delivery of large genes via dual AAV vectors. Its lead program, SB-007, is a dual AAV gene therapy designed to restore full-length ABCA4 protein expression for Stargardt disease. SB-007 received FDA IND clearance in December 2024, has Orphan Drug Designation from both the FDA and the European Commission, and obtained MHRA clearance to enter clinical development. The company is currently running the Phase 1/2 ASTRA interventional study (first patient dosed March 2025) and the POLARIS observational natural history study. Proceeds from the financing will support continued clinical development of SB-007 and accelerate SpliceBio's broader pipeline of AAV gene therapy programs in ophthalmology, neurology, and other undisclosed indications. SpliceBio leverages technology developed in the Muir Lab at Princeton University and is based in Barcelona, Spain. SpliceBio exploits Protein Splicing to develop the next generation of gene therapies and operates a proprietary platform that enables efficient delivery of large genes with adeno-associated vectors (AAV). The platform is designed to overcome AAV cargo-size limits by using intein and protein engineering approaches developed over more than 20 years in the Muir Lab at Princeton University. Led by CEO Miquel Vila-Perelló, the company intends to use its technology to build a pipeline of Protein Splicing gene therapy programs. Its lead program in Stargardt disease is being advanced toward the clinic. Financially, SpliceBio raised €50M in a Series A financing to support pipeline development and clinical advancement. The company was seeded in 2020 by Ysios Capital and Asabys Partners. Splice Bio, formerly ProteoDesign, develops intein-based technologies for gene therapy aimed at treating genetic diseases. Its platform, based on research carried out at Princeton by the company's cofounders, is designed to overcome key limitations of adeno-associated viral (AAV) vectors. The technology could enable treatments for diseases caused by mutations in large genes and broaden the range of organs that can be targeted. The company announced a new financing round to advance the development of these therapies. Proceeds will be used to develop new therapies for genetic diseases. Splice Bio also refreshed its brand to reflect its renewed focus on gene therapy. ProteoDesign is a biotechnology spin-out from Princeton University that develops personalized cancer immunotherapies. The company says it has a novel in-house protein-engineering platform discovered after more than 20 years of pioneering research. ProteoDesign announced the close of a €1.7 million funding round led by venture firm Caixa Capital Risc, with participation from a business angel. Caixa Capital Risc was already an existing investor in the company's shareholder base. The proceeds will be used to advance ProteoDesign's immunotherapy candidates through preclinical development.